Q-Line Biotech Announces Rs 214.48 Crore SME IPO

Mumbai: Q-Line Biotech, a Lucknow-based in-vitro diagnostics (IVD) and healthcare solutions company, has announced its Rs 214.48 crore Initial Public Offering (IPO). The company’s shares will be listed on the NSE Emerge platform.

The SME IPO will open on May 21, 2026, with a price band of Rs 326 to Rs 343 per equity share of face value Rs 10 each. The public issue will close on May 25, 2026.

The net proceeds from the IPO will be used to meet working capital requirements of Rs 110 crore, repay certain borrowings worth Rs 90 crore, and for general corporate purposes.

Q-Line Biotech is engaged in the manufacturing and supply of diagnostic reagents, rapid test kits, molecular diagnostics, pathology equipment, and related consumables used by hospitals and healthcare institutions.

The IVD market has witnessed significant shifts in recent years, mainly due to the COVID-19 pandemic. The market grew from USD 1,237 million in CY19 to USD 2,142 million in CY21, driven by increased testing demand during the pandemic. However, the sector saw a sharp decline in CY22 and CY23 due to reduced COVID-related testing and the high base effect.

With growing healthcare awareness and the rising prevalence of chronic diseases, the market started recovering in CY24 and is projected to grow at a CAGR of up to 12 per cent, reaching USD 2,978 million by 2030.